Tuberculosis Testing Market Size, Share & Trends Analysis Report By Diagnostic Test Type (Radiographic Test, Smear Microscopy, Culture-Based Test, Nucleic Acid Test, Cytokine Detection Test, Drug Resistance Test, Other Diagnostic Test Types), By End User (Hospital/Clinic, Diagnostics/Research) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2023-2031

Market Overview

The global tuberculosis testing market size was valued at USD 1.5 billion in 2022. It is projected to reach USD 2.24 billion by 2031, growing with a CAGR of 4.6% during the forecast period (2023–2031). 

Tuberculosis is a disease caused by bacteria of the genus mycobacteria. It mainly targets the lungs, but bacteria can also attack other body parts and cause infection of the genitourinary system, lymphatic system, and central nervous system. Pulmonary tuberculosis is a bacterial infection in the lungs, while infection in other body parts is extrapulmonary tuberculosis.

With the increasing number of TB patients all over the world, the demand for diagnosing kits or testing kits for TB is also increasing. Globally, the incidence of tuberculosis has been increasing at a faster rate each year. According to the India TB report 2022, the total number of incident TB patients, including both new and relapse cases, was 19.0% higher in 2021 than in 2020. Due to the high incidence rates of tuberculosis, governments in various nations have prioritized enhancing their healthcare expenditures for TB diagnosis and treatment. The growth of the tuberculosis testing market can be attributed to rising TB incidences, rising disease awareness, and rising demand for tuberculosis diagnostics to reduce the disease burden. In addition, the increasing focus of market participants on the approval and commercialization of their products for TB diagnostics has contributed to tuberculosis testing market growth.

Market Dynamics

What are the factors driving the tuberculosis testing market growth?

Favorable government policies

Governments have improved tuberculosis diagnosis policies to reduce the global tuberculosis burden. As countries become increasingly aware of the severity of the disease, it is anticipated that the demand for the diagnosis will increase over the next few years. Numerous nations have prioritized the development of policies to increase tuberculosis diagnosis rates. Factors such as the high prevalence of tuberculosis in high-burden nations and the rising demand for TB testing increase the need for government policies and regulations to improve tuberculosis diagnosis rates. In addition, the growing awareness in countries with a high prevalence of tuberculosis, where the primary objective is to reduce tuberculosis cases, is anticipated to significantly boost the sales of TB diagnostics in the coming years. 

What are the future opportunities for the tuberculosis testing market ?

Technologically advanced testing

There is a high demand for technologically advanced TB testing techniques that can increase the accuracy, reliability, speed, and ease of diagnosis. Examples include IGRA, fast TB tests, and diagnostic methods. Demand for new TB tests has increased globally due to advancements in culture-based tests that use liquid culture mediums and tests for drug sensitivity and antibiotic susceptibility. Demand for TB testing technologies is anticipated to increase with the introduction of cartridge-based nucleic acid amplification technology and the emergence of Cepheid's GeneXpert MTB/RIF in the field of nucleic acid-based tuberculosis testing.

Regional Analysis

Geographically, the global tuberculosis testing market has been segmented into North America, Europe, Asia Pacific, and LAMEA.

North America is projected to account for the largest share of the global tuberculosis testing market during the forecast period. The market is growing primarily due to high R&D expenditures, and the presence of significant market players in the US will accelerate this growth. The weakening of the immunity system due to chronic diseases such as HIV is an important cause of tuberculosis. According to the National Aids Control Organisation, in 2021, approximately 1.2 million people suffering from HIV in the United States. This prevalence of HIV has directly been leading to an increase in the incidences of tuberculosis, which, in turn, drives the market growth. The high incidence of respiratory diseases in the US places a heavy economic burden on the nation. In the upcoming years, it is anticipated that the country will require latent TB detection kits due to the increasing number of patients suffering from respiratory disorders and COPD. New market entrants, product launches, and rapidly growing healthcare facilities define North America's growth. The market for TB detection in North America is also anticipated to grow due to the aging population and rising rates of chronic diseases.

Europe accounts for a significant share of the global tuberculosis testing market, owing to the region's expanding geriatric population prone to chronic diseases. Moreover, the prominent presence of key regional players further supports market growth. The region's expansion is also due to initiatives taken by European government agencies to increase the number of diagnostic laboratories in important nations like the UK and the region's growing need for TB diagnostics, such as rapid molecular diagnostics.

Asia-Pacific is pegged to be the fastest-growing market during the forecast period. The Asia Pacific market is growing at a faster rate than other regions due to improvements in healthcare infrastructure, a high prevalence of TB disease, and rising consumer demand for better treatment outcomes. The improvement in healthcare infrastructure in Asian nations, the high prevalence of tuberculosis in this region, and the rising demand for improved treatment outcomes are driving the market growth rate in Asia and the Pacific. In India, government support and early diagnosis of tuberculosis are among the key factors propelling the market growth. The Indian government organizes various campaigns to raise awareness regarding tuberculosis, which in turn provides impetus to market growth. India has been observed to have the highest prevalence of tuberculosis and multidrug-resistant tuberculosis (MDR-TB) and the highest detection rate of new cases each year. In addition, the incidence of tuberculosis was estimated to be 193 per one million people in India in 2020. Consequently, the rising prevalence of MDR-TB cases among the population is anticipated to increase the demand for early diagnosis of the disease for subsequent treatment, which is expected to fuel market growth over the forecast period.

The LAMEA region is expected to witness substantial growth in the global market during the forecast period, owing to the increasing prevalence of tuberculosis and infrastructure improvement in the region. In addition, the growing geriatric population, increasing initiatives by manufacturers to broaden their product portfolio and improve the availability of advanced products in the Latin American region, and rising funding for the development of products are anticipated to drive the growth of the tuberculosis diagnostics market in the region. Countries in the Middle East have highly efficient healthcare systems. The UAE health sector is administered by two authorities: the Ministry of Health, which regulates the public health sector, and the Emirates health authorities, which is responsible for service delivery at the state level. The nation is one of the largest backers of TB eradication programs. The major factor driving the growth of the TB detection market in the Middle East and Africa is the expanding market in emerging economies and rising advances in tuberculosis testing.

Segmental Analysis

The global tuberculosis testing market can be segmented by diagnostic test type and end user.

Based on diagnostic test type, the market for tuberculosis testing can be segmented into radiographic tests, nucleic acid testing, cytokine detection test, drug resistance test, and other diagnostic test types.

The rapid molecular diagnostics segment dominates the market and is projected to maintain a sizeable market share over the forecast period. The segment's growth is attributed to the efficiency and accuracy associated with rapid molecular diagnostics for TB diagnosis. It is anticipated that new product launches in the rapid molecular diagnostics segment will contribute to its growth over the forecast period.

In addition, the segment of culture-based diagnostics is anticipated to grow substantially over the forecast period. The segment's expansion can be attributed to the escalating incidence of tuberculosis, which is driving an increase in demand for technologically advanced diagnostics that are both efficient and precise.

Based on end-user, the market can be segmented into hospital/clinic and diagnostics/research.

The hospital segment will dominate the market over the forecast period. A few factors driving this segment's growth include an increase in hospitalizations for the treatment of chronic illnesses, the availability of numerous supplies in hospital laboratories, and better patient-provider communication. The demand for tuberculosis testing procedures is also anticipated to increase due to the presence of skilled healthcare professionals in hospitals for effective and appropriate TB diagnosis, identification, and medication.

Due to the widespread presence of diagnostic laboratories, the segment is expanding. In addition, the segment's growth results from the rising prevalence of tuberculosis testing in these diagnostic laboratories.

Recent Developments

• October 2022 Illumina Inc., a leader in DNA sequencing and array-based technologies, -and GenoScreen, an innovative genomics company, announced a partnership to accelerate efforts to eradicate tuberculosis (TB) globally. The partnership will expand the capacity of countries most affected by tuberculosis to detect and combat multidrug-resistant TB more effectively. This partnership will enable global access to a package of Illumina sequencing products for rapid and extensive detection, thereby fast-tracking treatment decision-making.
• January 2021- PerkinElmer reached an agreement to acquire Oxford Immunotec, establishing it to compete with Qiagen in the infectious disease market. PerkinElmer will gain ownership of the T-SPOT TB test, a diagnostic that measures T cells against Mycobacterium tuberculosis antigens to detect active and latent TB infection. The test will be integrated into PerkinElmer's portfolio of immunodiagnostic products, many of which were acquired back-to-back acquisitions of Euroimmun and Tulip.